Track market-moving stories before they get noisy

The submission marks an important milestone in FMC's efforts to advance next-generation weed control technologies as resistance pressure intensifies in key row crop markets.

, /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced it has submitted the regulatory dossier for rimisoxafen to the United States (U.S.) Environmental Protection Agency (EPA), the first regulatory submission globally for this groundbreaking herbicide active ingredient. The U.S. submission covers use on corn, soybean, sunflower and select pulse crops.

"Filing the first regulatory dossier for rimisoxafen with the EPA represents a significant milestone for FMC," said Seva Rostovtsev, executive vice president and chief technology officer at FMC. "Years of innovation and scientific discovery have brought us to this point, and we are proud to advance this breakthrough dual mode of action technology through the regulatory process on behalf of growers facing increasingly complex weed resistance challenges."

Discovered at FMC's Stine Research Center and built on over a decade of biology research and more than 1,000 field and greenhouse studies, rimisoxafen is the first herbicide active ingredient ever classified as a dual mode of action by the Global Herbicide Resistance Action Committee (HRAC). Designated under Groups 12 and 32, rimisoxafen inhibits two distinct biochemical pathways in weeds, which helps delay resistance development compared to single mode of action herbicides.

Herbicide-resistant weeds continue to challenge growers and drive demand for new and underutilized modes of action. According to a 2025 Weed Science Society of America National Weed Survey, Palmer amaranth and waterhemp rank as the most troublesome broadleaf weeds in U.S. soybean production1. In extensive field testing, rimisoxafen has demonstrated consistent activity against both. The U.S. represents a critical market for next-generation weed control solutions with more than 70 million hectares of corn and soybeans grown annually and growers spending more than $6 billion annually on weed control.

Rimisoxafen is the third novel herbicide active ingredient FMC has advanced to regulatory submission in recent years, following Isoflex™ active and Dodhylex™ active. Together, these submissions reflect the depth and productivity of FMC's R&D pipeline and the company's commitment to advancing next-generation crop protection solutions through the regulatory process.

FMC intends to pursue regulatory submissions for rimisoxafen in additional key geographies and crop segments as part of its global development program. Timing and outcomes are subject to regulatory review and approval in each jurisdiction. Rimisoxafen is not currently registered for sale or use in the United States or any other country. No offer for sale, sale or use of this product is permitted prior to receipt of all required regulatory approvals.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

Dodhylex and Isoflex are trademarks of FMC Corporation and/or an affiliate. Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

1 Van Wychen, L. (2025). 2025 Survey of the Most Common and Troublesome Weeds in Broadleaf Crops, Fruits & Vegetables, and Hemp in the United States and Canada. Weed Science Society of America National Weed Survey Dataset. Available at: https://wssa.net/2025/11/wssa-survey-shows-an-urgent-need-for-new-weed-control-strategies/

SOURCE FMC Corporation

Invesco Nasdaq Biotechnology ETF offers a lower expense ratio and a higher trailing dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered a higher 1-year total return and experienced a less severe maximum drawdown than Invesco Nasdaq Biotechnology ETF.

Dycom Industries, Inc. (DY) Discusses Demand Drivers and Growth Prospects in Infrastructure Build Cycles July 8, 2026 11:00 AM EDT

Company Participants

Daniel Peyovich - CEO, President & Director

Conference Call Participants

Joseph Osha - Guggenheim Securities, LLC, Research Division

Presentation

Joseph Osha
Guggenheim Securities, LLC, Research Division

Great. Well, hi, everybody. Thanks very much for joining us today. I'm Joe Osha from Guggenheim Securities. We are joined by Dan Peyovich, who is the CEO of Dycom. Thanks very much for hosting. We appreciate it.

Daniel Peyovich
CEO, President & Director

Thanks for having.

Joseph Osha
Guggenheim Securities, LLC, Research Division

Yes. We're going to talk through a number of aspects of the business today. This is one-way thing only. So we're not taking questions. Although if any of you do have issues, you want me to address, you can e-mail me. Most of you know my e-mail, we'll try and get to them. But anyway, thanks for joining us.

Question-and-Answer Session

Joseph Osha
Guggenheim Securities, LLC, Research Division

Let's start off at a high level here, right? And I call this the why-now question. You just had a heck of a Q1, right, $12 billion in backlog. Is this just a cyclical upturn or is something more significant happening here? Is this the beginning of something secular?

Daniel Peyovich
CEO, President & Director

Yes, we've talked a lot about the different demand drivers, Joe. And again, thanks for the conversation today. Talked a lot about the different demand drivers and really where they're coming through the cycle. And I think one of the things we've really tried to impress on folks is there is a lot of room left to run. Even if you look at fiber to the home which has been out there for a while, a lot of room left to run and we can

SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all sellers of ChampionX Corporation (NASDAQ: CHX) common stock between February 29, 2024 and April 1, 2024. ChampionX is a global provider of chemistry solutions, artificial lift systems, and highly engineered equipment and technologies for the drilling and production of oil and gas.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations?

Shareholders allege that ChampionX Corporation repurchased shares of its stock in violation of securities laws. According to the complaint, during the class period, defendants repurchased 216,000 shares of ChampionX stock – worth millions of dollars – from unsuspecting investors without disclosing material nonpublic information about Schlumberger Limited’s (SLB) offers to purchase ChampionX at a premium to then-current prices. If this information had been disclosed as required, it would have indicated to investors that ChampionX’s stock was worth significantly more than its trading price.

Plaintiff alleges that when investors learned the truth that SLB was willing to buy all the Company's outstanding stock for a significant premium above the trading price, ChampionX's stock price climbed sharply, harming investors who sold during the class period.

What can shareholders do now? You may be eligible to participate in the class action against ChampionX Corporation. Shareholders who wish to serve as lead plaintiff for the class must submit their papers with the court by July 14, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against ChampionX Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Commvault Systems, Inc. (NASDAQ: CVLT) securities between April 29, 2025 and January 26, 2026. Commvault is a data protection company.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations?

Shareholders allege that Commvault Systems, Inc. misled investors regarding its annualized recurring revenue growth. According to the complaint, during the class period defendants created the false impression that Commvault’s annualized recurring revenue (ARR) growth would remain steady throughout fiscal year 2026. Plaintiff alleges that Commvault knew or recklessly disregarded that the Company’s ARR growth guidance failed to properly factor in crucial variables. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Commvault’s securities at artificially inflated prices.

Plaintiff alleges that the truth was revealed on January 27, 2026, when Commvault published third quarter 2026 fiscal results, which included ARR growth below the guidance provided by the Company. Commvault reported ARR growth for the third quarter 2026 was $39 million, which fell short of the $45 million projection provided. On this news, the price of Commvault’s common stock declined from a closing price of $129.36 per share on January 26, 2026, to $89.13 per share on January 27, 2026, a decline of over 31% in a single day.

What can shareholders do now? You may be eligible to participate in the class action against Commvault Systems, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers with the court by July 17, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Commvault Systems, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Editor’s note: This story has been updated to include a statement from Bloom Energy.

Bloom Energy told Benzinga that the company is aware of the report “published by a media outlet affiliated with an investment firm that has disclosed it may hold positions designed to profit from a decline in Bloom’s stock,” and plans to issue a response.

“We are reviewing the report and will correct the record. Bloom’s fuel cell platform is supported by a diversified, multi-country supply chain built over two decades, long-standing commercial relationships, and proprietary materials-recovery technology, as described in our public filings and our July 7 blog post on scandium oxide,” a Bloom Energy spokesperson said.

Executive Supply Chain Claims ContradictedThe decline follows findings by Hunterbrook challenging statements made by Bloom Energy CEO KR Sridhar regarding the company’s independence from Chinese materials.

Sridhar stated during an April 2025 earnings call, “We are not dependent on China for scandium,” adding, “there is no China supply chain for us.”

However, global trade data, corporate filings, and satellite imagery analyzed by the news outlet indicate that the fuel-cell manufacturer continues to rely on Chinese-sourced scandium, said Hunterbrook.

Hidden Routes And Supplier ConnectionsHunterbrook traced four separate China-linked routes delivering scandium into the manufacturer’s supply chain.

Deliveries involve direct shipments of scandium oxide from Hunan Oriental Scandium to a Delaware plant, as well as intermediaries routing materials through Thailand, Japan, and South Korea.

A sales representative from Hunan Oriental Scandium told reporters, “We are also BE’s largest supplier of scandium,” noting the material is “not exported directly.”

Widening Deficits And Delayed ProjectsHunterbrook’s supply-demand model indicates a looming global deficit for fuel-cell-grade scandium oxide.

The research shows Bloom Energy alone requires roughly 220 tons of scandium oxide to meet the 5 gigawatt production expectations modeled by Wall Street, while the total projected global supply reaches approximately 240 tons.

BE Stock Price Activity: Bloom Energy shares were down 9.89% at $242.91 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo by Michael Vi via Shutterstock

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Key Takeaways Healthcare robotics is expanding into surgery, diagnostics, lab automation and orthopedics. Robotics ETFs are adding more healthcare automation exposure alongside industrial robotics. ETFs like ROBO offer exposure to healthcare automation innovators alongside robotics and AI companies. While electric vehicles and tech giants like Tesla (TSLA - Free Report) and Alphabet (GOOGL - Free Report) dominate headlines in the robotics space, a powerful transformation has reached an inflection point in healthcare. Over the past decade, robotics in medicine has moved from early adoption to mainstream scale. 

This acceleration has been driven by an aging global population, a persistent shortage of skilled surgeons and clinical staff, and the increasing push for minimally invasive procedures that offer faster recovery times and better patient outcomes. What was once dominated by the use of robots in a handful of guided surgeries has now expanded into varied branches ranging from orthopedics and pharmacy automation to artificial intelligence (AI)-driven diagnostics.

For investors looking to capitalize on this clinical migration, the challenge lies in differentiation. While standard healthcare funds offer stable dividends, they often dilute the tech-driven upside of advanced engineering. 

Broad robotics exchange-traded funds (ETFs), which have historically prioritized factory automation, material handling, and semiconductor equipment suppliers, have expanded their allocation to med-tech innovators like Intuitive Surgical (ISRG - Free Report) in the recent past. 

Evaluating the true potential of these robotics ETFs requires a ground-up look at the dominant healthcare stocks leading the charge and the clinical market dynamics driving their bottom lines.

Pioneering Stocks in Healthcare RoboticsSeveral key healthcare stocks demonstrate the broad range of robotics applications across the medical field, a few of which are discussed below.

•    Intuitive Surgical: As the pioneer in robotic-assisted surgery, its da Vinci system is a household name, allowing for complex procedures through small incisions. The company continues to show strong performance for this product, with Da Vinci procedures having risen approximately 16% year over year in the first quarter of 2026. 

ISRG grew its da Vinci surgical system installed base to 11,395 systems as of March 31, 2026, reflecting an increase of 12%. The new da Vinci 5 platform is driving higher utilization, and its data-rich ecosystem is creating a long-term competitive advantage in AI.

•    Illumina (ILMN - Free Report) : While best known for its gene-sequencing technology, Illumina is a prime example of robotics in lab automation. The company developed robotic systems like the Infinium Automated Pipetting System, which automates highly labor-intensive sample preparation workflows, as well as Digital Microfluidics, which is a droplet-based automation technology that moves, merges, and mixes liquid droplets using electrical signals. This minimizes human error and dramatically reduces processing time, which are critical for large-scale genomic studies and clinical diagnostics.

•    Stryker (SYK - Free Report) : A major player in medical devices, Stryker is a leader in orthopedic robotics. Its Mako system is used for robotic-arm assisted total knee, partial knee, and total hip replacements, offering surgeons enhanced precision and control. This technology has benefited the company's financial performance.

From surgical precision to laboratory efficiency, these examples illustrate how robotics is becoming integral to modern healthcare delivery across multiple specialties.

Industry Outlook and the Role of ETFsAs technology advances, we are moving closer to AI-enhanced surgical systems that improve decision-making, micro-robotic devices capable of navigating the human body for targeted therapy, and autonomous diagnostic tools that assist in early disease detection.

Against this backdrop, the outlook for healthcare robotics is exceptionally bright. According to a report published by Johns Hopkins University in May 2025, the global healthcare robotics market is expected to increase from approximately $14.9 billion in 2023 to $57.0 billion by 2032. 

While picking a single winner in this rapidly growing $57 billion market can be challenging, investing in a specialized robotics ETF provides a more balanced entry point. Rather than relying on a single clinical breakthrough, these funds grant investors exposure to the entire robotics value chain. 

This diversified approach can potentially boost profits by capturing growth across industrial automation, logistics, and other sectors, while mitigating the risk associated with any single company or sub-sector.

Robotics ETFs to ConsiderFor investors looking to tap into the robotics industry’s pioneering growth prospects, the following ETFs stand out: 

Global X Robotics & Artificial Intelligence ETF (BOTZ - Free Report)  

This fund, with net assets worth $3.43 billion, offers exposure to 62 companies that potentially stand to benefit from increased adoption and utilization of robotics and AI, including those involved in industrial robotics and automation, non-industrial robots, and autonomous vehicles. Keyence Corp holds the first spot in this fund, with 9.69% weightage, while ISRG holds the fifth position with 6.72% weightage. 

BOTZ has rallied 13.1% over the past year. The fund charges 68 basis points (bps) as fees and traded at a good volume of 1.33 million shares in the last trading session. 

ROBO Global Robotics and Automation Index ETF (ROBO - Free Report)

This fund, with net assets worth $2.09 billion, offers exposure to 79 companies that are driving transformative innovations in robotics, automation, and artificial intelligence (RAAI), including companies that create technology to enable truly intelligent systems that can sense, process, and act, and companies that apply those technologies to deliver RAAI-enabled products, including robots, to businesses and consumers. Harmonic Drive Systems holds the first spot in this fund, with 1.92% weightage, while ISRG holds the fourth position with 1.77% weightage. ILMN holds the sixth spot in this fund, with 1.69% weightage. 

ROBO has surged 36.2% over the past year. The fund charges 95 bps as fees and traded at a volume of 0.29 million shares in the last trading session. 

First Trust NASDAQ Artificial Intelligence and Robotics ETF (ROBT - Free Report)

This fund, with net assets worth $728.2 million, offers exposure to 114 companies engaged in AI, robotics and automation. Palo Alto Networks holds the first spot in this fund, with 1.87% weightage, while ILMN holds the fourth position with 1.75% weightage. 

ROBT has risen 15% over the past year. The fund charges 65 bps as fees and traded at a volume of 0.03 million shares in the last trading session. 

HomeDividends AnalysisREITs AnalysisReal Estate Analysis

SummaryKimco Realty Corporation has a solid balance sheet — $19.58B in total assets, an investment-grade A-/A-/A3 credit rating, and an asset coverage ratio (Total Assets/Debt) of ~236%.Preferred stocks KIM.PR.L (~6.54% current yield) and KIM.PR.M (~6.6%) trade below par and carry investment-grade ratings (Baa1/BBB/BBB).KIM has a portfolio of 565 properties and 100 million sq ft of leasable area, with the largest share being occupied by the "Grocery and Beverages" and "Restaurants" sectors.This idea was discussed in more depth with members of my private investing community, Trade With Beta. Learn More » Getty Images

In today's article, we will look into Kimco Realty Corporation (KIM), its financial metrics and ratios from the last quarter, and its financial instruments. We will look to the opportunities that they provide to us, as at the current

15.81K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in KIM.PR.M over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Peabody Energy Corporation (NYSE: BTU) common stock between October 14, 2024 and May 4, 2026, inclusive (the "Class Period"), have until August 24, 2026 to seek appointment as lead plaintiff of the Peabody Energy class action lawsuit. Captioned McGeachy v. Peabody Energy Corporation, No. 26-cv-01020 (E.D. Mo.), the Peabody Energy class action lawsuit charges Peabody Energy as well as certain of Peabody Energy's top current and former executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Peabody Energy class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-peabody-energy-corporation-class-action-lawsuit-btu.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Peabody Energy engages in the production of metallurgical and thermal coal.

The Peabody Energy class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Peabody Energy's Centurion mine ramp-up and anticipated growth; and (ii) there was a multitude of issues causing delays to the Centurion mine ramp-up and the return to full longwall production dates.

On March 30, 2026, Peabody Energy issued a press release allegedly lowering guidance pertaining to Centurion mine's expected first quarter 2026 output by 450,000 tons ahead of Peabody Energy's full earnings release. On this news, the price of Peabody Energy stock fell nearly 10%, according to the complaint.

Then, on May 5, 2026, Peabody Energy issued a press release allegedly disclosing Peabody Energy's failure to ramp-up Centurion by the long-awaited March 2026 deadline and that Peabody Energy was cutting guidance related to full year met segment volumes to reflect the increased cost and substantial volume decrease. On this news, the price of Peabody Energy stock fell nearly 6%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Peabody Energy common stock during the Class Period to seek appointment as lead plaintiff in the Peabody Energy class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Peabody Energy class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Peabody Energy class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Peabody Energy class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:
          Robbins Geller Rudman & Dowd LLP
          Ken Dolitsky
          Michael Albert
          655 W. Broadway, Suite 1900, San Diego, CA 92101
          800/851-7783
          [email protected]

SOURCE Robbins Geller Rudman & Dowd LLP

July 08, 2026 16:10 ET  | Source: Monster Beverage Corporation

CORONA, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Monster Beverage Corporation (NASDAQ: MNST) today announced that its Board of Directors has approved and declared a 2-for-1 split of its common stock that will be effected in the form of a 100% stock dividend. Each stockholder of record on July 24, 2026 will receive a dividend of one additional share of common stock for each then-held share, to be distributed after close of trading on August 10, 2026. The Company anticipates its common stock to begin trading at the split-adjusted price on August 11, 2026.

Monster Beverage Corporation
Based in Corona, California, Monster Beverage Corporation is a holding company and conducts no operating business except through its consolidated subsidiaries. The Company’s subsidiaries develop and market energy drinks, including Monster Energy® drinks, Monster Energy Ultra® energy drinks, Juice Monster® and Punch Monster® Energy + Juice energy drinks, Java Monster® and Monster Killer Brew® non-carbonated coffee + energy drinks, Rehab® Monster® non-carbonated energy drinks, Monster Energy® Nitro energy drinks, Reign Total Body Fuel® high performance energy drinks, Reign Storm® and Storm™ total wellness energy drinks, NOS® energy drinks, Full Throttle® energy drinks, Bang Energy® drinks, FLRT™ total wellness energy drinks, BPM® energy drinks, BU® energy drinks, Burn® energy drinks, Live+® energy drinks, Mother® energy drinks, Nalu® energy drinks, Play® and Power Play® (stylized) energy drinks, Relentless® energy drinks, Samurai® energy drinks, Ultra Energy® drinks, Predator® energy drinks and Fury® energy drinks. The Company’s subsidiaries also develop and market craft beers, flavored malt beverages and hard seltzers under a number of brands, including Jai Alai® IPA, Dale’s Pale Ale®, Dallas Blonde®, Wild Basin® hard seltzers, The Beast™, Beast® Tea, Blind Lemon® and Blinder Lemon™. For more information visit www.monsterbevcorp.com.

Caution Concerning Forward-Looking Statements

Certain statements made in this announcement may constitute “forward-looking statements” within the meaning of the U.S. federal securities laws, as amended, regarding the expectations of management with respect to our future operating results and other future events including revenues and profitability. The Company cautions that these statements are based on management’s current knowledge and expectations and are subject to certain risks and uncertainties, many of which are outside of the control of the Company, that could cause actual results and events to differ materially from the statements made herein. Such risks and uncertainties include, but are not limited to, the following: the timing and completion of the stock split; our ability to sustain and/or surpass the current level of sales of our products, to adapt to changing consumer preferences, and to effectively respond to competitive products and pricing pressures; our ability to implement our growth strategy, including expanding our business in existing and new sectors and achieving profitability within our Alcohol Brands segment; our ability to adapt to the changing retail landscape with the rapid growth in e-commerce retailers and e-commerce websites; our ability to absorb, reduce or pass on to our bottlers/distributors increases in costs and expenses, including, but not limited to, increases to the cost of aluminum and other raw materials, the Midwest Premium, and freight costs; the impact of the current U.S. presidential administration’s policies on our energy drinks due to concerns about sugar-sweetened beverages, particular ingredients, such as food dyes, and the “generally recognized as safe” (GRAS) process; the impact of proposed or adopted domestic and/or foreign legislation to limit or restrict the sale of energy drinks (including the prohibition of the sale of energy drinks to certain demographics, at certain establishments, in certain container sizes or pursuant to certain governmental programs, such as the Supplemental Nutrition Assistance Program (SNAP)); the impact of changes in U.S. trade policies, including the imposition of additional tariffs; the impact of adverse changes in our costs, our supply chain, inflation or consumer demand for our products; the imposition of new and/or increased excise sales and/or other taxes on our products; our extensive commercial arrangements with The Coca-Cola Company (TCCC) and, as a result, our future performance’s substantial dependence on the success of our relationship with TCCC; the effects of unilateral decisions by bottlers/distributors and/or retailers on our business, including their distribution and placement of our products, their consolidation, their discontinuation, or restriction of the range of, all or any of our products that they carry, their limitations on the sale or sizes of our products, and/or their allocation of less resources to the sale of our products; changes in the price and/or availability of raw materials and other supply chain issues, such as the availability of products, suitable production facilities and/or co-packing arrangements; possible recalls of our products and/or the consequences and costs of defective production; disruption to our manufacturing facilities and operations related to climate, labor, production difficulties, capacity limitations, regulations or other causes; disruption to and/or lack of effectiveness of our information technology systems, including internal and external cybersecurity threats and breaches; adverse publicity surrounding obesity, alcohol consumption and other health concerns related to our products, product safety and quality; liabilities resulting from legal or regulatory proceedings, government investigations, and/or injunctions; the inherent operational risks, including the abuse or misuse of our products presented by the alcoholic beverage industry and/or related claims that may not be adequately covered by insurance or may lead to litigation; the current uncertainty and volatility in the national and global economy and changes in demand due to such economic conditions, including a slowdown in consumer spending generally; and the impact of military conflicts, including supply chain disruptions, volatility in commodity prices, increased economic uncertainty and escalating geopolitical tensions. For a more detailed discussion of these and other risks that could affect our operating results, see the Company’s reports filed with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2025 and our subsequently filed quarterly report. The Company’s actual results could differ materially from those contained in the forward-looking statements. The Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:Mark Astrachan SVP, Investor Relations & Corporate Development (951) 739-6200   Roger S. Pondel / Judy Lin PondelWilkinson Inc. (310) 279-5980

, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws.  

IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed "profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier" and that "[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue."

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%,  to close at $59.49 per share on April 29, 2026.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100, 
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice
Persons with non-public information regarding GE HealthCare should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

SOURCE Glancy Prongay Wolke & Rotter LLP

Key Takeaways GKOS rallied after positive iDose TR commentary eased concerns over proposed Medicare coverage restrictions.GKOS reported $54M in first-quarter iDose TR sales and expects sequential growth in the second quarter.Glaukos is expanding with Epioxa adoption and a broad ophthalmology pipeline supporting long-term growth. Shares of Glaukos (GKOS - Free Report) have surged 45.7% since the end of May. The stock has outpaced the industry’s 4% gain and the S&P 500 Index’s 0.9% decline.

GKOS stock witnessed a sharp rally after the company announced better-than-expected first-quarter top and bottom-line figures on April 29. However, the stock pared all its gains in May amid uncertainty surrounding the proposed Local Coverage Determination (LCD) for its glaucoma therapy, iDose TR, by Medicare Administrative Contractors (MACs).

The MACs have proposed providing coverage for iDose only to patients who have failed both selective laser trabeculoplasty (SLT) and two topical medications. The proposal also restricts the concurrent use of iDose TR with minimally invasive glaucoma surgery (MIGS) procedures and limits re-administration of iDose TR to once every two years. These proposed restrictions could hurt the drug's commercial prospects.

However, Glaukos management seemed confident about receiving an exclusion or modification on some or all of these restrictions in the final LCD draft, while presenting at several investor conferences held during the end of May or early June. The company is focusing on promoting iDose TR as first-line treatment for ocular hypertension.

One-Month Performance

Image Source: Zacks Investment Research

GKOS management also stated that the market opportunity for iDose TR remains significant despite the proposed restrictions, driven by the rising number of glaucoma cases, and reaffirmed its guidance for 2026 and 2027. The company also believes that many patients are ineligible for SLTs or topical medications or both. GKOS is conducting a phase 4 study to evaluate the use of iDose TR with MIGS procedure, which has demonstrated promising results so far.

Several analysts also believe that the proposed restrictions for iDose TR in the proposed LCDs will have a minimal impact on its sales going forward. They expect a sizable pool of patients who have undergone selective laser trabeculoplasty (SLT) over the past decade to remain eligible for iDose TR.

The recent rally in Glaukos shares can be primarily attributed to investor enthusiasm following the positive commentary on iDose TR.  The company recorded $54 million in iDose TR sales during the first quarter of 2026. GKOS expects sales of the therapy to grow sequentially in the second quarter as well.

Other Factors Supporting the Rally

Rising Epioxa Adoption:Apart from iDose TR, Epioxa is emerging as Glaukos' next major growth engine, with management reporting an encouraging commercial launch despite being in its earliest phase. The company has rapidly built a treatment network covering nearly 65% of the U.S. population, with visibility to expand coverage to roughly 95%.

Reimbursement momentum is strengthening, supported by access pathways covering more than 100 million commercial lives. The drug is covered by four of the five largest U.S. payers and received a permanent J-code effective July 2026. Combined with direct-to-consumer awareness campaigns and physician education initiatives, these developments position Epioxa to meaningfully expand the underpenetrated keratoconus treatment market over time.

Strong Pipeline:Glaukos continues to differentiate itself through one of ophthalmology's broadest innovation pipelines, with 13 publicly disclosed programs spanning glaucoma, corneal disorders, retinal diseases and ocular surface therapies. Beyond commercial products like iDose TR and Epioxa, the company is advancing iDose TREX, iStent infinite for earlier-stage glaucoma, and PRESERFLO MicroShunt, iLution for Demodex blepharitis.

The company plans to initiate studies on next-generation iLink technologies and a keratoconus screening device later this year. Management also highlighted promising early-stage retinal assets and multiple Phase 4 studies that could expand reimbursement, strengthen clinical evidence and create additional label-expansion opportunities, supporting sustainable long-term growth beyond its current revenue drivers.

Key Challenges

Despite strong execution, Glaukos faces several operational challenges that could moderate near-term growth. Apart from uncertainty surrounding iDose TR LCDs, Epioxa's launch remains constrained by reimbursement complexity until the permanent J-code becomes fully operational, resulting in temporary claims-processing delays and slower physician adoption.

The company also expects international glaucoma growth to decelerate due to increasing competitive product launches and fading foreign-exchange tailwinds. Furthermore, management plans to accelerate investments in commercial infrastructure, patient awareness and direct-to-consumer initiatives, which will keep operating expenses elevated and delay margin expansion.

In addition, successful commercialization depends on increasing keratoconus diagnosis rates and expanding physician adoption, requiring sustained investment in education, payer engagement and market development before Epioxa can fully realize its long-term billion-dollar revenue potential.

A Glance at GKOS’ Estimates

The Zacks Consensus Estimate for GKOS’ 2026 loss per share is pinned at 57 cents, implying a year-over-year improvement of 36.7%. The Zacks Consensus Estimate for 2027 earnings per share is pegged at 47 cents, implying growth of 181% year over year. In the past 60 days, the consensus mark for the company's earnings has remained stable.

Revenues for 2026 are projected to grow 23.7% to $627.6 million and another 26.6% to $794.3 million in 2027.

Image Source: Zacks Investment Research

GKOS’ Zacks Rank and Stocks to Consider

Currently, Glaukos has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of 52 cents, which surpassed the Zacks Consensus Estimate by 52.94%. Revenues of $139 million beat the Zacks Consensus Estimate by 6.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 5.1% for 2026 compared with the industry’s 14% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 45.88%.

West Pharmaceutical, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.37%.

Intuitive Surgical, carrying a Zacks Rank of 2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.3% compared with the industry’s 12.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%

Key Takeaways Denali gained 59.4% YTD as Avlayah approval marked its shift to a commercial-stage company.DNLI will receive $195 million from selling its Rare Pediatric Disease Priority Review Voucher.DNLI regained full rights to DNL593 after Takeda ended the partnership for strategic reasons. Denali Therapeutics, Inc. (DNLI - Free Report) has put up a stupendous year-to-date performance. Shares of the company have surged 59.4% year to date compared with the industry’s growth of 5.9%. The stock has outperformed the sector and the S&P 500 Index during this time frame.

The rally is largely attributed to investor optimism surrounding FDA approval of its lead drug, Avlayah, for the treatment of Hunter syndrome, as well as other regulatory updates.

DNLI Outperforms Industry, Sector & S&P 500 Index
Image Source: Zacks Investment Research

While the approval serves as a major catalyst, a deeper assessment of the company's growth drivers and potential risks will be essential to determine whether current levels represent an attractive entry point.

Avlayah Approval Positions DNLI for Long-Term UpsideAvlayah is an enzyme replacement therapy indicated for pediatric patients with Hunter syndrome (MPS II), targeting neurological symptoms when initiated early.

Developed by Denali, Avlayah is enabled by its TransportVehicle platform, which facilitates delivery of biologics throughout the body, including the brain.

Approval was based on strong biomarker data, showing a 91% reduction in cerebrospinal fluid heparan sulfate levels, a key disease marker.

This accelerated approval is particularly noteworthy as it introduces the first new therapeutic option for this rare disorder in nearly two decades. The continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory study.

Denali’s ongoing global phase II/III COMPASS study is expected to provide confirmatory data and support regulatory filings for tividenofusp alfa-eknm worldwide, including in young adult patients with Hunter syndrome.

The approval came with a Rare Pediatric Disease Priority Review Voucher (“PRV”).

Last month, DNLI entered into a definitive agreement to sell its PRV, which is expected to generate gross proceeds of $195 million.

The added financial flexibility will help advance Denali’s broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases.

DNLI’s Other Pipeline CandidatesDenali's clinical-stage portfolio includes DNL126 for Sanfilippo syndrome type A (MPS IIIA), DNL593 for GRN-related frontotemporal dementia, DNL952 for Pompe disease and DNL628 for Alzheimer's disease.

Denali is also advancing several early-stage pipeline candidates, including DNL921 for Alzheimer's disease, DNL111 for Parkinson’s and Gaucher diseases, DNL622 for Hurler syndrome (MPS I), and DNL422 (OTV) for Parkinson’s disease.

Denali has also collaborated with other pharma and biotech giants like Sanofi (SNY - Free Report) , Biogen (BIIB - Free Report) and Takeda (TAK - Free Report) to develop other candidates.

In May 2026, Denali and partner Biogen announced disappointing top-line results from a mid-stage study evaluating BIIB122 (DNL151) in individuals with early-stage Parkinson’s disease. The study did not meet its primary or secondary endpoints.

Biogen and Denali have discontinued the development of BIIB122 in idiopathic Parkinson’s disease.

Nonetheless, Denali will continue to independently advance the phase IIa BEACON study evaluating the small-molecule inhibitor in patients carrying pathogenic LRRK2 variants.

Partner Sanofi is developing eclitasertib for moderate-to-severe ulcerative colitis.

In April 2026, Denali announced that partner Takeda decided to terminate their collaboration for DNL593 (PTV:PGRN) in frontotemporal dementia associated with GRN mutations (FTD-GRN).

The termination returns full rights to the program to Denali. According to DNLI, Takeda's decision was driven by strategic priorities rather than any efficacy or safety concerns.

However, Takeda’s exit may raise concerns. Even though the decision was not tied to safety or efficacy, the loss of a large pharma partner removes external validation and shared financial burden.

Denali’s Valuation and EstimatesGoing by the price/book ratio, DNLI’s shares currently trade at 4.51X, higher than its mean of 3.02X for the industry and the industry’s mean of 3.64X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 loss per share has narrowed to $2.77 from $2.90 over the past 60 days, while that for 2027 loss has narrowed to $2.53 from $2.69 in the same time frame.

Image Source: Zacks Investment Research

Invest in DNLI Stock NowThe approval of Avlayah represents Denali’s transition into a commercial-stage company and a potential inflection point in its long-term growth trajectory. As its first marketed product, Avlayah introduces a new revenue stream, though the pace and scale of commercialization will be critical in determining its ultimate financial impact.

Beyond near-term revenues, the approval also validates Denali’s proprietary TransportVehicle platform, which is designed to enable biologic therapies to cross the blood-brain barrier — an area that has historically posed significant challenges.

On the financial front, Denali appears well capitalized, ending the first quarter with approximately $1.05 billion in cash and investments. This provides sufficient runway to support ongoing clinical development and strategic initiatives. Narrowing loss estimates indicate improving investor sentiment and a clearer path toward operational leverage.

The sale of PRV provides a significant non-dilutive capital infusion, strengthening the company’s balance sheet without requiring an equity raise.

We remain bullish on the stock's prospects and believe it offers additional upside potential. Accordingly, we view the shares favorably for prospective investors, while existing shareholders may consider maintaining their positions to capitalize on further growth opportunities.

Key Takeaways VIAV lifted non-GAAP operating margin to 21% as NSE and OSP revenue posted strong year-over-year growth.VIAV expects operating margin to reach 22.7% in the fourth quarter, up from 21% in the third quarter.VIAV's earnings estimates for 2026 were unchanged, while 2027 estimates improved over the past 60 days. Viavi Solutions, Inc. (VIAV - Free Report) reported a non-GAAP operating income of $85.5 million, up from $47.7 million a year ago quarter. Non-GAAP operating margin was 21%, up from 16.7% a year ago.

The improvement in operating margin is driven by multiple factors, including strong growth in the Network and Service Enablement segment (NSE) and Optical Security and Performance Products (OSP). In the third quarter of fiscal 2026, the NSE segment generated $321.5 million in revenues, up 54.4% year over year. The segment accounted for 79% of total revenues. Acquisition of Spirent product lines and strong demand across lab, production and field products, mainly from the data center ecosystem and aerospace & defense sectors, drove solid sales growth in this segment. The OSP segment revenues were $85.3 million, up 11.4% year over year, driven by strong demand for 3D Sensing and anti-counterfeiting.

Higher revenue is allowing fixed costs to be spread across a larger sales base. This is resulting in a significant operating leverage. Every incremental dollar of NSE revenue contributes roughly 40-45 cents to operating income, reflecting a highly scalable cost structure. Increasing mix, AI infrastructure and data center business, backed by hyperscalers’ demand, investment by optical module vendors and semiconductor companies will likely drive operating margin in the coming quarters. In the fourth quarter, Viavi expects its operating margin to reach 22.7%, up from 21% in the third quarter.

Other Tech Firms With Strong Margin ExpansionSanmina Corporation (SANM - Free Report) reported a non-GAAP operating profit of $257 million in the second quarter of 2026, up from $111 million a year ago. Non-GAAP operating margin improved to 6.4% from 5.6%. The 131.5% increase year over year and an 80-basis point operating margin expansion are driven by a multitude of factors. The ZT system, which performed significantly better than expected, was one of the biggest contributors. Strong customer demand for accelerated compute systems and earlier-than-expected shipments supported Sanmina’s profitability. Sanmina’s revenues surged 102.3% year over year to $4.01 billion. Revenue growth significantly outpaced the increase in operating expenses. Disciplined cost management was also a key contributor in this regard.

HubSpot. Inc. (HUBS - Free Report) generated a non-GAAP operating income of $156.8 million, up from $100.3 million in the prior-year quarter, with margin expanding 380 basis points year over year to 17.8%. Higher revenues and operating discipline helped offset increased investments in research, AI innovation and sales initiatives. HubSpot continues to witness rising adoption among larger customers as businesses consolidate marketing, sales and service workflows on a unified AI-enabled platform. During the first quarter of 2026, deals above $60,000 in annual recurring revenues increased 37% year over year, while deals above $120,000 ARR rose 64%. HubSpot’s AI strategy is increasingly contributing to customer engagement and monetization.

VIAV’s Price Performance, Valuation and EstimatesViavi has gained 290.8% in the past year compared with the Electronics - Measuring Instruments industry’s growth of 287%.

Image Source: Zacks Investment Research

Going by the price/earnings ratio, the company’s shares currently trade at 32.8 forward earnings, lower than 41.94 for the industry and its mean of 37.66.

Image Source: Zacks Investment Research

The company’s earnings estimates for 2026 have remained unchanged and 2027 have improved over the past 60 days.

Image Source: Zacks Investment Research

VIAV carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The tribunal on Wednesday determined that Prime Medicine’s investigational gene-editing therapy PM647 falls within the scope of the companies’ 2019 Collaboration and License Agreement.

The decision clears the company of any breach of contract claims and eliminates any financial liability related to the case.

Tribunal Rules PM647 Falls Within Prime Medicine’s Licensed FieldAccording to Prime Medicine, the arbitration tribunal concluded that PM647 is covered under the company’s defined “Field” in the 2019 agreement with Beam Therapeutics.

As a result, the tribunal found that Prime Medicine did not violate the terms of the agreement.

The company added that the ruling also determined it owes no monetary damages to Beam Therapeutics, bringing the previously disclosed arbitration to a close.

PM647 Targets Most Common Cause of Alpha-1 Antitrypsin DeficiencyPM647 is Prime Medicine’s investigational Prime Editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).

The therapy uses the company’s universal liver lipid nanoparticle (LNP) delivery platform to correct the E342K (Pi*Z) mutation in the SERPINA1 gene, which the company said is the most common disease-causing mutation associated with AATD.

Prime Medicine said that in fully humanized mouse models, PM647 achieved high editing efficiency while restoring the corrected M-AAT protein isoform to healthy human levels at clinically relevant doses.

Clinical Development Timeline Remains On TrackFollowing the arbitration outcome, Prime Medicine said it remains on schedule to advance PM647 into the clinic.

The company plans to submit an investigational new drug application and/or a clinical trial application for PM647 during the third quarter of 2026.

If those filings proceed as planned, Prime Medicine expects to report initial clinical data from the program in 2027.

PRME Price Action: Prime Medicine shares were up 13.16% at $4.51 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo by Gorodenkoff via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

BridgeBio Pharma (BBIO - Free Report) is building its investment case around rare diseases where diagnosis, targeted treatment and commercial access are changing quickly.

Attruby's launch in transthyretin amyloid cardiomyopathy gives the company a commercial base, while late-stage programs could widen its reach in genetic diseases with limited approved options.

Attruby Shows BridgeBio Demand ExpansionAttruby is already BridgeBio's main revenue driver. The drug generated $362.4 million in U.S. sales in 2025, its first full year on the market, and nearly $181 million in first-quarter 2026 sales.

The demand backdrop matters as much as the product launch. BridgeBio estimates diagnosed ATTR-CM patients in the United States increased from fewer than 5,000 in 2019 to more than 50,000 in 2025 as awareness improved and non-invasive diagnostic tools gained wider use.

This makes Attruby part of a broader market-expansion story. A larger identified patient pool can support continued adoption if BridgeBio converts diagnosis growth into prescriptions and maintains access against entrenched alternatives.

BBIO Targets First-in-Class OpportunitiesBridgeBio's late-stage pipeline is aimed at rare diseases where established therapies remain limited. BBP-418 is under FDA review for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with a decision expected by Nov. 27, 2026.

If approved, BBP-418 would become the first therapy for that patient group and potentially the first approved treatment for any form of limb-girdle muscular dystrophy. Encaleret offers a similar first-in-class angle in autosomal dominant hypocalcemia type 1 (ADH1), with a possible U.S. launch in early 2027.

The strategy fits BridgeBio's broader focus on genetically defined diseases. It also gives investors multiple regulatory catalysts beyond Attruby, although approval timing and label breadth remain key variables.

How Oral Drugs Shape BridgeBio's PositioningProduct format is part of BBIO's competitive pitch. Infigratinib is an orally administered therapy being developed for achondroplasia, with a U.S. filing planned for the third quarter of 2026.

That oral profile could matter in a market that already includes injectable options. BioMarin Pharmaceutical (BMRN - Free Report) markets Voxzogo in achondroplasia, while Ascendis Pharma (ASND - Free Report) adds another competitive reference point through Yuviwel.

Attruby also operates in a competitive field. Pfizer (PFE - Free Report) remains the established player in ATTR-CM through its Vyndaqel family, which means BridgeBio must compete on clinical relevance, access and physician adoption rather than diagnosis growth alone.

BridgeBio Builds Beyond a One-Product StoryBridgeBio is still highly dependent on Attruby, but its portfolio points beyond a single commercial win. The company is preparing for three potential U.S. launches over the next 12 months, supported by a $1 billion preferred equity financing.

Earlier-stage assets add a longer runway. BBP-812 is being developed for Canavan disease, while a next-generation ATTR-CM depleter program could extend BridgeBio's presence in the same cardiac amyloidosis market over time.

Minority interests in GondolaBio and BridgeBio Oncology Therapeutics add rare disease and oncology optionality. These assets are not central to the near-term thesis, but they reinforce the company's effort to build a broader genetic-disease platform.

How BBIO Signals Trend Strength to InvestorsThe bottom line is that BridgeBio gives investors credible exposure to rare disease diagnosis growth, targeted therapy development and underpenetrated patient populations. Attruby validates the commercial side, while BBP-418, encaleret and infigratinib could determine whether BBIO becomes a broader launch story.

BBIO currently carries a Zacks Rank #3 (Hold). That rank is consistent with a balanced view in which launch execution and market expansion are offset by competition, regulatory risk and valuation pressure. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

For now, the investment debate rests less on the attractiveness of rare disease trends and more on execution. Attruby must keep gaining share, and the pipeline needs approvals that can diversify revenues without adding avoidable launch risk.

The AI infrastructure boom is still in its early days. Alphabet (GOOG 2.04%) (GOOGL 1.89%) has initiated an $84.75 billion equity capital raise "to expand AI infrastructure and compute," while Amazon (AMZN 1.23%) more recently issued over $25 billion in corporate bonds for AI investments.

All that money has to go somewhere, and some of it can flow into Sterling Infrastructure's (STRL 2.03%) coffers. The construction company has turned into a top AI data center builder, and as demand for those facilities rises, Sterling Infrastructure will continue to build on its backlog.

Image source: Getty Images.

The e-infrastructure opportunity Sterling Infrastructure is a site development specialist for residential and commercial properties. It also helps with transportation infrastructure, which includes highways, roads, and bridges. Those parts of the business had moderate growth in the first quarter, but they were completely overshadowed by e-infrastructure.

Today's Change

(

-2.03

%) $

-13.68

Current Price

$

660.71

That's the part of the business that's focused on AI data centers, e-commerce warehouses, and advanced manufacturing facilities. Its revenue was up by 174% year over year in the quarter, and a $5.15 billion backlog offers clear revenue visibility for multiple years. Sterling Infrastructure was recently awarded a contract to develop a large, multi-year semiconductor fabrication campus. The company has secured the initial developmental phase of that project and could end up building the entire facility.

AI infrastructure demand won't be slowing down anytime soon. Alphabet and Amazon are going deep into their pockets and raising capital to build more sites and buy key components that enable AI technology. E-infrastructure has served as a major catalyst, and if its revenue continues to accelerate, overall sales will go up with it.

Assessing the 30% drop Although Sterling Infrastructure enjoys solid fundamentals and AI spending continues to climb, the stock is down by more than 30% from all-time highs. Furthermore, it's down by more than 20% over the past month. This isn't a Sterling Infrastructure problem, since many AI stocks have endured sharp corrections over the past month.

Even Micron (MU +0.93%) wasn't safe. More than quadrupling revenue year over year wasn't enough for the company to avoid a 20% downturn in less than two weeks.

The fact that many AI stocks and tech companies are in the middle of corrections indicates that Sterling Infrastructure is not suffering from company-specific issues. Its fundamentals are improving despite the sell-off, and investors will soon pick up on that opportunity.

Sterling Infrastructure's full-year revenue projections also point to meaningful expansion. It's expected to reach $3.75 billion in total revenue at the midpoint, which represents a 50.6% year-over-year growth rate from the $2.49 billion in total revenue in full-year 2025.

While some investors are cashing out, others can benefit by investing in the dip and capitalizing on long-term AI tailwinds at a discount.

Marc Guberti has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Micron Technology, and Sterling Infrastructure. The Motley Fool has a disclosure policy.

Helen of Troy Limited (HELE) Q1 2027 Earnings Call Transcript

Domino's Pizza Inc (NYSE:DPZ) is expected to report weaker-than-expected US same-store sales for the second quarter as macroeconomic pressures, elevated promotional activity across the pizza category and tougher year-over-year comparisons weigh on performance, according to UBS.

Ahead of the company's July 20 earnings report, the brokerage wrote that investors are likely to focus on current and planned sales initiatives, as well as management's outlook for sales in the second half of the year.

UBS forecasts US same-store sales will decline 1.5% in the second quarter, compared with Wall Street consensus expectations for 0.3% growth. The analysts wrote that softer consumer spending and heightened promotional competition are likely to offset benefits from value offers, marketing investments, the company's loyalty program and third-party delivery partnerships.

The firm expects management to highlight initiatives aimed at improving sales momentum, including continued value promotions, further growth through DoorDash, enhancements to Domino's app and loyalty platform, increased marketing and new menu offerings.

UBS also expects the company to discuss product innovation, including new sauces, expanded chicken options and additional crust platforms following the launch of Parmesan Stuffed Crust. The analysts added that store closures among competitors could help Domino's expand its market share over time.

While UBS continues to view Domino's as well-positioned for longer-term market share gains and global expansion, it sees risks to the company's current 2026 guidance.

UBS wrote that it sees downside risk to the company's current 2026 guidance, including low-single-digit growth in US and international same-store sales and mid- to high-single-digit operating income growth, excluding foreign exchange effects and the benefit of a 53rd week.

Outside the US, UBS forecasts global net store growth of 4.6% in the second quarter, in line with consensus estimates, including 31 net new stores in the US and 165 internationally. The analysts noted that global expansion outside Domino's Pizza Enterprises remains a relative strength, supported by attractive franchise economics, strong franchisee profitability, competitor closures and contributions from key international markets.

UBS added that investors are also likely to focus on Domino's Pizza Enterprises, including the arrival of its new chief executive in August, management's confidence in its turnaround strategy and potential portfolio changes to improve performance.

The firm maintained its $375 price target, saying Domino's valuation appears near a support level despite ongoing macroeconomic uncertainty, with longer-term upside supported by the company's potential to gain market share and accelerate sales growth through its strategic initiatives.

Shares of Domino’s traded hands at $305 on Wednesday afternoon.

CALGARY, Alberta, July 08, 2026 (GLOBE NEWSWIRE) -- Brookfield Residential Properties ULC (“Brookfield Residential” or the “Company”) today announced that its 2026 second quarter results will be released after market closes on Wednesday, July 29, 2026. The financial results and information relating to the 2026 second quarter will be posted on the Company’s website at BrookfieldResidential.com.

Current holders and beneficial owners of, and prospective investors in, Brookfield Residential’s debt securities, securities analysts, market makers and other interested parties are invited to participate in the conference call on Thursday, July 30, 2026 at 11:00 am (EST) to discuss the Company’s results of operations during the second quarter of 2026 and current business initiatives with members of senior management. To participate in the live conference call from North America, dial 1.833.821.3184 and if you reside outside of North America, dial 1.647.846.2582. Telephone replay of the conference call will be available for one month following the scheduled call, until end of day August 30, 2026. To listen to the telephone replay from the United States or Canada, dial 1.855.669.9658, and if you reside outside of the United States or Canada dial 1.412.317.0088. Once prompted enter the replay access code, 8343650.

Brookfield Residential Properties ULC is a leading land developer and homebuilder in North America.  We entitle and develop land to create master-planned communities, build and sell lots to third-party builders, and conduct our own homebuilding operations. We also participate in select, strategic real estate opportunities, including infill projects, mixed-use developments, and joint ventures. We are the flagship North American residential property company of Brookfield Corporation (NYSE: BN; TSX: BN), a global alternative asset manager. Further information is available at BrookfieldResidential.com or Brookfield.com or contact:

Investor Relations
Tel: 855.234.8362
Email: [email protected]

D-Wave Quantum Inc (NYSE:QBTS) was last seen off 2.7% to trade at $20.50, poised to nab its fifth loss in the past five sessions and trading at its lowest levels in over a month. However, a historically bullish signal now flashing points to a potential rebound.

According to Schaeffer's Senior Quantitative Analyst Rocky White, QBTS is trading within 0.75 times the 100-day moving average's 20-day average true range (ATR), after spending at least 80% of the previous two weeks and 80% of the prior 42 trading sessions above that trendline.

This setup has appeared five times over the last decade, after which the stock was higher one month later 60% of the time, averaging an impressive 28% gain. A similar move from the stock's current perch would have it trading at $26.24.

Short interest remains elevated with the 55.75 million shares sold short now accounting for 15.54% of QBTS' available float, and it would take short sellers roughly two days to buy back their bearish bets at the stock's average pace of trading.

It's also worth noting the equity's Schaeffer's Volatility Index (SVI) of 98% stands higher than just 20% of all other readings from the past year, implying that near-term option traders are pricing in relatively low volatility expectations.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

SanDisk (NASDAQ:SNDK | SNDK Price Prediction | SNDK Price Prediction) has become the strangest stock in the S&P 500. Shares are up 634.87% year to date, dwarfing the 67.8% gain on the VanEck Semiconductor ETF. Behind the move is a genuine business transformation.

Q3 FY26 revenue hit $5.95 billion, up 251.03% year over year, with datacenter revenue exploding 645%. CEO David Goeckeler called it “a fundamental inflection point for Sandisk”. Can SanDisk shares reach $2,500 by 2027? There is a real path, but it is not a straight line.

Why SanDisk Shares Have Stalled This Summer The stock is down 14.92% over the past week despite being up 11.87% over one month.

Two factors are at play. First, a broader semiconductor sell-off tied to South Korean semiconductor weakness jolted the group in late June. Second, investors are booking profits after one of the sharpest rallies in memory-chip history.

Alpha Vantage flagged “SanDisk Slides as Chip Sell-Off Jolts Investors” and questioned whether the name is overbought at a trailing P/E of 60. Beta sits at 1, but realized volatility is much higher given the 52-week range from $40.10 to $2,354.39. That disconnect is keeping shares stuck.

Wall Street Sees Upside. Our Model Wants Proof The Street is decisively bullish. The consensus 12-month target is $1,930.50, with 3 Strong Buys, 15 Buys, 3 Holds, and 1 Sell. Bulls have gone further: Bernstein moved to $3,000 and China Renaissance reached $3,169. Our model is more cautious.

The one-year base case sits at $1,642.21, a total return of -5.86% with 90% confidence, driven by a mega-cap dampening factor. The bull case reaches $2,417.53. Earnings growth is contributing positively to the 247Factor, and 82% of analysts are bullish. That is a meaningful signal.

The Path to $2,500 Per Share Reaching $2,500 from today’s price of $1,744.43 would require a 43.3% gain. With forward EPS of $32.68, a price of $2,500 implies a forward P/E of 77x. Our base case of $1,642.21 already implies 56x, meaning the bold target requires roughly 20x of additional multiple expansion.

The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.

That is steep. But three things could get it done. Q4 FY26 guidance calls for revenue of $7.75B to $8.25B and non-GAAP EPS of $30 to $33. If those numbers hit, forward EPS will re-rate sharply higher and the implied multiple compresses.

Second, the New Business Model is real. Goeckeler said multi-year customer commitments are “driving structurally higher and more durable earnings power”.

Third, on July 3, 2026, SanDisk began sampling BiCS10 1Tb TLC 3D NAND with a 59% improvement in bit density, positioning the company inside the AI memory buildout. A resurgence of the sector sell-off is the primary risk.

Where SanDisk Trades Today Versus Its Earnings Power At $1,744.43, shares trade at a forward P/E of roughly 53x on $32.68 forward EPS. That is not cheap, but not absurd for a company printing 78.4% gross margins with a zero-debt balance sheet and $2.99 billion in quarterly free cash flow.

Shares sit 18% below the 52-week high, well within reach on any renewed NAND cycle. Since separating from Western Digital, SNDK has rallied over 3,489%. That history sets a wide range of possible outcomes.

Is $2,500 Realistic? Here’s My Take Getting SanDisk to $2,500 by 2027 requires a 43.3% gain from here. I think that is a stretch, but not a long shot.

Three things need to go right: Q4 EPS lands at the high end of guidance near $33, the New Business Model contracts continue accumulating, and the structural memory undersupply extends through 2027 as Bank of America expects. A pricing crack in NAND would derail it fast. We’ve outlined the blueprint for how SanDisk could reach $2,500 in 2027.

If You'd Bought Amazon When the Motley Fool Said To…In September 2002, Stock Advisor told subscribers to buy Amazon. In December 2004, Netflix. In April 2005, Nvidia. The newsletter still publishes two new stock picks every month — and over 23 years, has more than quadrupled the S&P 500. Here's how to get this month's picks:

- Join Stock Advisor for one year, with a 30-day money-back guarantee

- Get this month's two new picks — plus the Top 10 Rankings and the full historical pick list

- Read the analysis, decide for yourself, and trade through your own brokerage

Five years from now, you'll probably wish you'd bought this month's picks. Don't miss them.

Contact [email protected] for any questions or corrections.

The memory-chip complex has sold off hard from recent peaks. In light of this, investors are asking which of Micron Technology (NASDAQ:MU | MU Price Prediction), SanDisk (NASDAQ:SNDK), or Applied Materials (NASDAQ:AMAT) they should actually own after the drawdown.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Futu To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Futu between May 24, 2023 and May 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - July 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Futu Holdings Limited("Futu" or the "Company") (NASDAQ: FUTU) and reminds investors of the August 25, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Futu was not in compliance with the requirements of the CSRC, including because the Company continued to conduct securities business, public fund sales business and futures business in mainland China without obtaining the requisite licenses or approval; (2) as a result, Futu was reasonably likely to face regulatory penalties, including the disgorgement of ill-gotten gains and other penalties; (3) as a result of the foregoing, Futu's financial results were overstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On May 22, 2026, pre-market, Futu issued a press release allegedly disclosing that it had received a notification letter from the CSRC stating that "certain Futu entities in mainland China and Hong Kong . . . without obtaining the requisite licenses or approval, conducted securities business, public fund sales business and futures business in mainland China" and that the CSRC "proposes to order the Related Companies to rectify or cease such activities, confiscate illegal gains, and impose fines, with the total proposed penalty amounting to approximately RMB1.85 billion (approximately USD271 million)." The Futu class action lawsuit further alleges that the regulatory authority "proposes to impose a personal fine of RMB1.25 million (approximately USD 183,575) on Mr. LI Hua, the founder and CEO of the Company." On this news, the price of Futu stock fell more than 27%, according to the complaint.

Then, on May 28, 2026, before the market opened, Futu issued a press release reporting financial results for the first quarter of 2026, allegedly including the proposed penalties comprised of "(i) confiscation of illegal gains of approximately RMB470 million [approximately $69.21 million USD] and (ii) imposition of fines of approximately RMB1.38 billion in an aggregate amount of approximately RMB1.85 billion." On this news, the price of Futu stock declined nearly 5%, according to the complaint.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Futu's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Futu Holdings Limited class action, go to www.faruqilaw.com/FUTU or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Futu Holdings Limited Securities Class Action Lawsuit:

What is the Futu Holdings Limited securities fraud lawsuit about?

The lawsuit alleges that Futu misled investors by failing to disclose it was conducting certain securities, public fund sales, and futures businesses in mainland China without required CSRC licenses or approvals. According to the complaint, this exposed the Company to significant regulatory penalties, overstated its financial results, and made its public statements about its business and prospects materially misleading.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired Futu Holdings Limited (NASDAQ: FUTU) securities between May 24, 2023 and May 27, 2026, inclusive (the "Class Period"), and suffered losses may be eligible to participate in the securities class action. Eligibility depends on the specific facts of each investor's transactions and losses.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is the investor appointed by the court to represent the interests of all class members during the litigation. Generally, the investor with the largest financial interest who meets the legal requirements may be selected. Investors seeking appointment must file a motion with the court by the August 25, 2026 deadline through counsel of their choice.

What should investors do if they purchased Futu Holdings Limited stock during the Class Period?

Investors who purchased Futu securities during the Class Period should review their investment records, preserve relevant documents, and consider contacting counsel to understand their legal rights. Those interested in serving as lead plaintiff must act before the August 25, 2026 deadline, while investors who do not seek that role may still remain eligible to share in any potential recovery.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Futu Holdings Limited securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304424

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Blue Bird (BLBD - Free Report) , which belongs to the Zacks Automotive - Domestic industry, could be a great candidate to consider.

When looking at the last two reports, this school bus maker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 24.23%, on average, in the last two quarters.

For the last reported quarter, Blue Bird came out with earnings of $1 per share versus the Zacks Consensus Estimate of $0.81 per share, representing a surprise of 23.46%. For the previous quarter, the company was expected to post earnings of $0.8 per share and it actually produced earnings of $1 per share, delivering a surprise of 25.00%.

Price and EPS Surprise

With this earnings history in mind, recent estimates have been moving higher for Blue Bird. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Blue Bird has an Earnings ESP of +3.00% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner.

When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.